Skip to Content
Søk Menu

ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL

The ELEVATE-TN study offers compelling long-term data on acalabrutinib’s effectiveness in treating chronic lymphocytic leukemia, showcasing sustained benefits and safety over 74.5 months.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Ingrid Glimelius

High Infection Burden and Mortality in CLL Patients: A Call for Action

/ Ingrid Glimelius
ASH24CLL Play the Video 02:15
Paolo Ghia

Pirtobrutinib Outperforms Investigators’ Choice in Relapsed/Refractory CLL After BTK Inhibitor Therapy

/ Paolo Ghia
ASH24CLL Play the Video 03:54
Jennifer R Brown

Deep and Durable Response of Fixed-Duration Acalabrutinib in Combination with Venetoclax, +/- Obinutuzumab in Previously Untreated Adults with CLL

/ Jennifer R. Brown
ASH24CLL Play the Video 04:11
Florian Simon

Acalabrutinib Shows Promise for Elderly CLL Patients

/ Florian Simon
ASH24CLL Play the Video 05:20

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24
Paolo Ghia

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

/ Paolo Ghia
CLLEHA24 Play the Video 02:42
Alessandra Tedeschi

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

/ Alessandra Tedeschi
CLLEHA24 Play the Video 01:52

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymfom Play the Video 01:08
Back to top